Blood pressure variability, impaired autonomic function and vascular senescence in aged spontaneously hypertensive rats are ameliorated by angiotensin blockade

Atherosclerosis

Volumn 236, Issue 1, 2014, Pages

  Sueta, Daisuke ^a   Koibuchi, Nobutaka ^a   Hasegawa, Yu ^a   Toyama, Kensuke ^a   Uekawa, Ken ^a   Katayama, Tetsuji ^a   Ma, MingJie ^a   Nakagawa, Takashi ^a   Waki, Hidefumi ^b   Maeda, Masanobu ^b   Ogawa, Hisao ^a   Kim Mitsuyama, Shokei ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin; Blood pressure variability; Circadian blood pressure; Oxidative stress; Vascular senescence

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; BETA GALACTOSIDASE; NORADRENALIN; OLMESARTAN; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; N(G) NITROARGININE METHYL ESTER; P22-PHOX PROTEIN, RAT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TETRAZOLE DERIVATIVE; VALINE;

AGING; ANIMAL EXPERIMENT; ARTICLE; AUTONOMIC DYSFUNCTION; BLOOD PRESSURE VARIABILITY; CIRCADIAN RHYTHM; DRUG EFFECT; HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TELEMETRY; URINARY EXCRETION; VASCULAR BIOLOGY; VASCULAR SENESCENCE; ANALOGS AND DERIVATIVES; ANIMAL; AORTA; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; DRUG SCREENING; GENETICS; HEART MUSCLE; ORGAN SIZE; PATHOLOGICAL REFLEX; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URINE; VASCULAR ENDOTHELIUM; VASODILATATION; WISTAR KYOTO RAT;

AGING; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA; AUTONOMIC NERVOUS SYSTEM; BAROREFLEX; BETA-GALACTOSIDASE; BLOOD PRESSURE; DRUG EVALUATION, PRECLINICAL; ENDOTHELIUM, VASCULAR; HYPERTENSION; IMIDAZOLES; MYOCARDIUM; NADPH OXIDASE; NG-NITROARGININE METHYL ESTER; NOREPINEPHRINE; ORGAN SIZE; OXIDATIVE STRESS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; REFLEX, ABNORMAL; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; VALINE; VASODILATION;

EID: 84905862555     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.06.016     Document Type: Article

References (38)

1. Drayer J.I., Weber M.A., DeYoung J.L., Wyle F.A. Circadian blood pressure patterns in ambulatory hypertensive patients: effects of age. Am J Med 1982, 73(4):493-499.
2. Gribbin B., Pickering T.G., Sleight P., Peto R. Effect of age and high blood pressure on baroreflex sensitivity in man. Circ Res 1971, 29(4):424-431.
3. O'Rourke M.F., Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. JAm Coll Cardiol 2007, 50(1):1-13.
4. Shimada K., Kitazumi T., Sadakane N., Ogura H., Ozawa T. Age-related changes of baroreflex function, plasma norepinephrine, and blood pressure. Hypertension 1985, 7(1):113-117.
5. Verdecchia P., Angeli F., Mazzotta G., Garofoli M., Ramundo E., Gentile G., et al. Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. Hypertension 2012, 60(1):34-42.
6. Verdecchia P., Porcellati C., Schillaci G., Borgioni C., Ciucci A., Battistelli M., et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994, 24(6):793-801.
7. Hastie C.E., Jeemon P., Coleman H., McCallum L., Patel R., Dawson J., et al. Long-term and ultra long-term blood pressure variability during follow-up and mortality in 14,522 patients with hypertension. Hypertension 2013, 62(4):698-705.
8. Hata J., Arima H., Rothwell P.M., Woodward M., Zoungas S., Anderson C., et al. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation 2013, 128(12):1325-1334.
9. Rothwell P.M. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 2010, 375(9718):938-948.
10. Rothwell P.M. Does blood pressure variability modulate cardiovascular risk?. Curr Hypertens Rep 2011, 13(3):177-186.
11. Rothwell P.M., Howard S.C., Dolan E., O'Brien E., Dobson J.E., Dahlof B., et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010, 375(9718):895-905.
12. Suchy-Dicey A.M., Wallace E.R., Mitchell S.V., Aguilar M., Gottesman R.F., Rice K., et al. Blood pressure variability and the risk of all-cause mortality, incident myocardial infarction, and incident stroke in the cardiovascular health study. Am J Hypertens 2013, 26(10):1210-1217.
13. Cui H., Kohsaka A., Waki H., Bhuiyan M.E., Gouraud S.S., Maeda M. Metabolic cycles are linked to the cardiovascular diurnal rhythm in rats with essential hypertension. PLoS One 2011, 6(2):e17339.
14. de la Sierra A., Redon J., Banegas J.R., Segura J., Parati G., Gorostidi M., et al. Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension 2009, 53(3):466-472.
15. deBoer R.W., Karemaker J.M., Strackee J. Hemodynamic fluctuations and baroreflex sensitivity in humans: a beat-to-beat model. Am J Physiol 1987, 253(3 Pt 2):H680-H689.
16. Del Colle S., Milan A., Caserta M., Dematteis A., Naso D., Mulatero P., et al. Baroreflex sensitivity is impaired in essential hypertensives with central obesity. JHum Hypertens 2007, 21(6):473-478.
17. Forstermann U., Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006, 113(13):1708-1714.
18. Minamino T., Komuro I. Vascular cell senescence: contribution to atherosclerosis. Circ Res 2007, 100(1):15-26.
19. Yildiz O. Vascular smooth muscle and endothelial functions in aging. Ann N. Y Acad Sci 2007, 1100:353-360.
20. Rothwell P.M., Howard S.C., Dolan E., O'Brien E., Dobson J.E., Dahlof B., et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010, 9(5):469-480.
21. Webb A.J., Fischer U., Mehta Z., Rothwell P.M. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 2010, 375(9718):906-915.
22. Webb A.J., Rothwell P.M. Effect of dose and combination of antihypertensives on interindividual blood pressure variability: a systematic review. Stroke 2011, 42(10):2860-2865.
23. Benigni A., Corna D., Zoja C., Sonzogni A., Latini R., Salio M., et al. Disruption of the Ang II type 1 receptor promotes longevity in mice. JClin Investig 2009, 119(3):524-530.
24. Diz D.I., Lewis K. Dahl memorial lecture: the renin-angiotensin system and aging. Hypertension 2008, 52(1):37-43.
25. Kim S., Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000, 52(1):11-34.
26. Kunieda T., Minamino T., Nishi J., Tateno K., Oyama T., Katsuno T., et al. Angiotensin II induces premature senescence of vascular smooth muscle cells and accelerates the development of atherosclerosis via a p21-dependent pathway. Circulation 2006, 114(9):953-960.
27. Sueta D., Kataoka K., Koibuchi N., Toyama K., Uekawa K., Katayama T., et al. Novel mechanism for disrupted circadian blood pressure rhythm in a rat model of metabolic syndrome - the critical role of angiotensin II. JAm Heart Assoc 2013, 2(3):e000035.
28. Kudo H., Kai H., Kajimoto H., Koga M., Takayama N., Mori T., et al. Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation. Hypertension 2009, 54(4):832-838.
29. Michel M.C., Foster C., Brunner H.R., Liu L. Asystematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 2013, 65(2):809-848.
30. Takai S., Jin D., Ikeda H., Sakonjo H., Miyazaki M. Significance of angiotensin II receptor blockers with high affinity to angiotensin II type 1 receptors for vascular protection in rats. Hypertens Res 2009, 32(10):853-860.
31. Timmermans P.B., Wong P.C., Chiu A.T., Herblin W.F., Benfield P., Carini D.J., et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993, 45(2):205-251.
32. Parati G., Ochoa J.E., Lombardi C., Bilo G. Assessment and management of blood-pressure variability. Nat Rev Cardiol 2013, 10(3):143-155.
33. Ambasta R.K., Kumar P., Griendling K.K., Schmidt H.H., Busse R., Brandes R.P. Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. JBiol Chem 2004, 279(44):45935-45941.
34. Fukui T., Ishizaka N., Rajagopalan S., Laursen J.B., Capers Qt, Taylor W.R., et al. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 1997, 80(1):45-51.
35. Ushio-Fukai M., Zafari A.M., Fukui T., Ishizaka N., Griendling K.K. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. JBiol Chem 1996, 271(38):23317-23321.
36. Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of ageing. Nature 2000, 408(6809):239-247.
37. Kurz D.J., Decary S., Hong Y., Trivier E., Akhmedov A., Erusalimsky J.D. Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells. JCell Sci 2004, 117(Pt 11):2417-2426.
38. Linz W., Wiemer G., Gohlke P., Unger T., Scholkens B.A. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995, 47(1):25-49.